This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Peptides & Oligonucleotides

The future of peptide vaccines and personalized peptide therapies - WHITEPAPER

Synthetic peptide vaccines are a nascent but highly promising therapeutic class. The field unites cancer biology and infectious disease treatment principles. There is, however, a key difference, a cancer vaccine is not prophylactic. Even though infectious disease  prophylactic vaccines, such as against HPV, can prevent cancer, personalized cancer vaccines are an active treatment of an existing tumor. This whitepaper focuses on exciting future of peptide cancer and infectious disease vaccines, exploring:

- Synthetic peptide vaccines
- Personalized cancer vaccines
- Tumor neoantigen vaccines
- Companies developing cancer peptide vaccines
- Improving formulation consistency of individualized, peptide-based therapies
- Regulatory view of personalized medicine concepts

To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email

This piece represents the views of the author and not necessarily the views of Informa Connect Life Sciences or the TIDES conference series.

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.